Moran Kyle 4

Accession 0001193125-25-314736

CIK 0001631574other

View on SEC.gov Company Profile

Filed

Dec 9, 7:00 PM ET

Accepted

Dec 10, 9:45 PM ET

Size

31.0 KB

Accession

0001193125-25-314736

Insider Transaction Report

Form 4

Period: 2025-12-08

Wave Life Sciences Ltd.WVE

Moran Kyle

Chief Financial Officer

Transactions

Exercise/Conversion
Ordinary Shares
2025-12-08$2.83/sh+60,000$169,800→ 149,218 total
Sale
Ordinary Shares
2025-12-08$13.20/sh−60,000$792,000→ 89,218 total
Exercise/Conversion
Ordinary Shares
2025-12-08$3.14/sh+100,000$314,000→ 189,218 total
Sale
Ordinary Shares
2025-12-08$15.00/sh−50,000$750,000→ 139,218 total
Exercise/Conversion
Ordinary Shares
2025-12-08$4.75/sh+50,000$237,500→ 139,218 total
Exercise/Conversion
Ordinary Shares
2025-12-09$8.17/sh+36,000$294,120→ 125,218 total
Sale
Ordinary Shares
2025-12-09$20.25/sh−36$729→ 89,218 total
Exercise/Conversion
Ordinary Shares
2025-12-09$10.48/sh+50,000$524,000→ 139,218 total
Sale
Ordinary Shares
2025-12-09$20.02/sh−50,000$1,001,250→ 90,365 total
Award
Share Option (right to buy)
2025-12-08−60,000→ 0 total
Exercise: $2.83Exp: 2032-07-25→ Ordinary Shares (60,000 underlying)
Award
Share Option (right to buy)
2025-12-08−100,000→ 75,000 total
Exercise: $3.14Exp: 2032-01-01→ Ordinary Shares (100,000 underlying)
Award
Share Option (right to buy)
2025-12-08−50,000→ 222,700 total
Exercise: $4.75Exp: 2033-02-17→ Ordinary Shares (50,000 underlying)
Award
Share Option (right to buy)
2025-12-09−36,000→ 0 total
Exercise: $8.17Exp: 2030-03-03→ Ordinary Shares (36,000 underlying)
Award
Share Option (right to buy)
2025-12-09−50,000→ 0 total
Exercise: $10.48Exp: 2031-02-01→ Ordinary Shares (50,000 underlying)

Footnotes (7)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025.
[F2]These share options are fully vested.
[F3]The share option represented a right to purchase a total of 175,000 ordinary shares that vest as to 25% of the shares on January 1, 2023 and vests as to an additional 6.25% of the shares quarterly thereafter until January 1, 2026.
[F4]The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.00 to $15.045 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
[F5]The share option represented a right to purchase a total of 272,200 ordinary shares that vest as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027.
[F6]The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $20.00 to $20.22 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
[F7]Includes 1,147 ordinary shares acquired on July 14, 2025, under the issuer's 2019 Employee Share Purchase Plan.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

Wave Life Sciences Ltd.

CIK 0001631574

→

Entity typeother

Related Parties

filerCIK 0001657765

Filing Metadata

Form type: 4
Filed: Dec 9, 7:00 PM ET
Accepted: Dec 10, 9:45 PM ET
Size: 31.0 KB

View on SEC.gov